Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs – Aptinyx (NASDAQ:APTX)
[ad_1] In March, Aptinyx Inc APTX completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress…
Top Stories Thursday, Mar. 30: Microsoft To Place Ads In ChatGPT Powered Bing Search, Netflix Preps For Big Transition Into TV Gaming, Coinbase Says US 1M Tech Jobs At Risk
[ad_1] Benzinga Coinbase Warns Unclear Crypto Regulations Pose Threat To 1M US Tech Jobs Cryptocurrency exchange Coinbase Inc COIN says that one million tech jobs are at risk of being outsourced…
Novo Nordisk’s Obesity Drug May Find Place On World Health Organization’s ‘Essential Medicines List’ – Novo Nordisk (NYSE:NVO)
[ad_1] For the first time World Health Organization is reportedly considering adding obesity drugs to its “essential medicines list,” used to guide government purchasing decisions in low- and middle-income countries,…
AstraZeneca Axes Pneumonia Drug Pact With Aridis – AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF), Aridis Pharmaceuticals (NASDAQ:ARDS)
[ad_1] AstraZeneca plc AZN scrapped its license agreement with Aridis Pharmaceuticals Inc ARDS. With the license terminated for AR-320 (suvratoxumab), the ongoing AR-320-003 Phase 3 clinical study must be put on…
Why Bluebird Bio (BLUE) Shares Are Plunging Today – bluebird bio (NASDAQ:BLUE)
[ad_1] Bluebird Bio Inc BLUE shares are plummeting after the company signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release. In early…
FDA Removes Partial Clinical Hold From Blueprint Medicines’ Cancer Study – Blueprint Medicines (NASDAQ:BPMC)
[ad_1] The FDA lifted the partial clinical hold on Blueprint Medicines Corporation’s BPMC Phase 1/2 VELA trial of BLU-222. In February, the agency placed a partial clinical hold on the VELA trial…
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose – Moderna (NASDAQ:MRNA)
[ad_1] From now on, Moderna Inc MRNA expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. “There are different…
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information – AstraZeneca (NASDAQ:AZN), BioNTech (NASDAQ:BNTX)
[ad_1] President Joe Biden signed legislation requiring the Office of the Director of National Intelligence to declassify information on any possible links between a lab in China and the origins of…
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics – Nurix Therapeutics (NASDAQ:NRIX), Gilead Sciences (NASDAQ:GILD)
[ad_1] Gilead Sciences Inc GILD has exercised its option to license Nurix Therapeutics Inc’s NRIX investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from…
BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics’ Lead Cancer Candidate – Leap Therapeutics (NASDAQ:LPTX)
[ad_1] Leap Therapeutics Inc LPTX announced BeiGene Ltd’s BGNE option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired. The companies announced an option agreement in…
FDA Advisory Committee Votes Favoring Pfizer’s COVID-19 Pill Paxlovid – Pfizer (NYSE:PFE)
[ad_1] The FDA’s Antimicrobial Drugs Advisory Committee voted 16-1 that available data support the safety and effectiveness of Pfizer Inc’s PFE Paxlovid for mild-to-moderate COVID-19 in adult patients who are at high risk…
Why Paratek Pharmaceuticals (PRTK) Stock Is Plunging Today – Paratek Pharmaceuticals (NASDAQ:PRTK)
[ad_1] Paratek Pharmaceuticals Inc’s PRTK Q4 total revenue o reached $75.6 million compared to $31.8 million a year, beating the consensus of $63.45 million. Nuzyra net U.S. sales of $66.4 million,…
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study – Protagonist Therapeutics (NASDAQ:PTGX)
[ad_1] Protagonist Therapeutics Inc PTGX announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera, causing the bone marrow to make too many red blood…
Silicon Valley Bank Creditors Purchased Bonds At Distressed Levels Anticipating Potential Bankruptcy Sale – SVB Finl Gr (NASDAQ:SIVB)
[ad_1] Silicon Valley Bank’s parent, SVB Financial Group’s SIVB creditors, have formed a group in the case of a potential bankruptcy filing. The PJT Partners Inc PJT-advised group is anticipating the fallen bank to…
Retail Sales Fall In February, Marginally More Than Expected – SPDR S&P 500 (ARCA:SPY)
[ad_1] The Census Bureau released U.S. retail and food services sales that were down 0.4% M/M compared with -0.3% consensus and 3.2% growth in January and up 5.4% above February 2022. Total…
GSK’s Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales – GSK (NYSE:GSK)
[ad_1] by Vandana Singh, Benzinga Editor March 15, 2023 7:22 AM | 2 min read GSK Plc’s GSK top scientist, Tony Wood, who took the helm of R&D last August,…
Data For Pfizer’s COVID-19 Drug Shows No Possible Association With Infection Rebound – Pfizer (NYSE:PFE)
[ad_1] The FDA dropped in briefing document as the agency’s external advisors meet on Thursday (March 16) to discuss complete approval for Pfizer Inc’s PFE Covid-19 treatment drug Paxlovid. Data from the…
Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step – Seagen (NASDAQ:SGEN), Pfizer (NYSE:PFE)
[ad_1] Pfizer Inc PFE has agreed to acquire Seagen Inc SGEN for $229 in cash per Seagen share for a total enterprise value of $43 billion. “Pfizer is deploying its financial resources…
Why Aridis Pharmaceuticals (ARDS) Shares Are Soaring Today – Aridis Pharmaceuticals (NASDAQ:ARDS)
[ad_1] Aridis Pharmaceuticals Inc ARDS announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The…
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs – bluebird bio (NASDAQ:BLUE), Amgen (NASDAQ:AMGN)
[ad_1] New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc’s (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900…
Why Bionomics (BNOX) Shares Are Soaring Today – Bionomics (NASDAQ:BNOX)
[ad_1] Bionomics Limited BNOX released a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210 for the acute treatment of Social Anxiety…
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births – Walgreens Boots Alliance (NASDAQ:WBA), iShares Biotechnology ETF (NASDAQ:IBB)
[ad_1] Privately held-Covis Pharma, the maker of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth, said it is moving to withdraw the medication from the market…
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason – SPDR Select Sector Fund – Health Care (ARCA:XLV), iShares Biotechnology ETF (NASDAQ:IBB)
[ad_1] The Health Care Select Sector SPDR Fund XLV, heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies reporting annual earnings. Shares of Health Care Select Sector…
Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’ – Medtronic (NYSE:MDT)
[ad_1] Medtronic plc MDT announced that its PulseSelect Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event…
Why BioMarin (BMRN) Shares Are Plunging Today? – Biomarin Pharmaceutical (NASDAQ:BMRN)
[ad_1] Biomarin Pharmaceutical Inc BMRN shares are falling in reaction to positive data from BridgeBio Pharma Inc’s BBIO dwarfism drug, heating the competition. At the highest dose level evaluated to date…